Cue Biopharma Announces Changes to its Board of Directors

NEXT STORY
AB Science provides update on masitinib programs timelines
PREV STORY
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017

MELBOURNE, Australia and NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) ...

author_avatar
NASDAQ Market News

T2 Biosystems Announces Customer Presentations at October Conferences

IDWeek and World Antimicrobial Resistance Congress to feature presentations on T2Bacteria and T2Candida PanelsLEXINGTON, ...

author_avatar
NASDAQ Market News

Vical to Present HSV-2 Phase 1/2 Data at June ASM Microbe/ICAAC 2016 Conference

SAN DIEGO, June 13, 2016 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that ...

author_avatar
NASDAQ Market News